These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 26817158)

  • 21. The isolated polycystin-1 COOH-terminal can activate or block polycystin-1 signaling.
    Basavanna U; Weber KM; Hu Q; Ziegelstein RC; Germino GG; Sutters M
    Biochem Biophys Res Commun; 2007 Jul; 359(2):367-72. PubMed ID: 17540339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The TRPP subfamily and polycystin-1 proteins.
    Semmo M; Köttgen M; Hofherr A
    Handb Exp Pharmacol; 2014; 222():675-711. PubMed ID: 24756726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of porcine polycystic kidney disease 1 (PKD1) gene: molecular cloning, expression profile, and implication in disease model.
    He J; Wang Q; Ye J; Hu X; Li N
    Gene; 2011 Dec; 490(1-2):37-46. PubMed ID: 21945688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.
    Gattone VH; Wang X; Harris PC; Torres VE
    Nat Med; 2003 Oct; 9(10):1323-6. PubMed ID: 14502283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human disease: calcium signaling in polycystic kidney disease.
    Somlo S; Ehrlich B
    Curr Biol; 2001 May; 11(9):R356-60. PubMed ID: 11369247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Linkage analysis excludes the involvement of the canine PKD2 homologue in bull terrier polycystic kidney disease.
    O'Leary CA; Duffy D; Biros I; Corley S; Seddon JM
    Anim Genet; 2006 Oct; 37(5):527-8. PubMed ID: 16978192
    [No Abstract]   [Full Text] [Related]  

  • 27. Identification of novel glycans with disialylated structures in α3 integrin from mouse kidney cells with the phenotype of polycystic kidney disease.
    Zhang AF; Wu SL; Jung Y; Qin S; Hancock WS; Kreidberg JA
    J Proteome Res; 2014 Nov; 13(11):4901-9. PubMed ID: 25300029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
    Spichtig D; Zhang H; Mohebbi N; Pavik I; Petzold K; Stange G; Saleh L; Edenhofer I; Segerer S; Biber J; Jaeger P; Serra AL; Wagner CA
    Kidney Int; 2014 Jun; 85(6):1340-50. PubMed ID: 24402093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polycystin-1: function as a mechanosensor.
    Dalagiorgou G; Basdra EK; Papavassiliou AG
    Int J Biochem Cell Biol; 2010 Oct; 42(10):1610-3. PubMed ID: 20601082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro cystogenesis: the search for drugs antagonizing cyst development.
    Ibraghimov-Beskrovnaya O; Bukanov NO
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S109-14. PubMed ID: 17373209
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystic gene dosage influences kidney lesions after nephron reduction.
    Le Corre S; Viau A; Burtin M; El-Karoui K; Cnops Y; Terryn S; Debaix H; Bérissi S; Gubler MC; Devuyst O; Terzi F
    Nephron; 2015; 129(1):42-51. PubMed ID: 25531116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polycystins: from mechanosensation to gene regulation.
    Delmas P
    Cell; 2004 Jul; 118(2):145-8. PubMed ID: 15260985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [TRPP subfamily and kidney diseases].
    Zhao J; Yang W; Luo JH
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Nov; 39(6):650-6. PubMed ID: 21166062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy.
    Harris PC; Torres VE
    Curr Opin Nephrol Hypertens; 2006 Jul; 15(4):456-63. PubMed ID: 16775462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Polycystic kidney disease in 2011: Connecting the dots toward a polycystic kidney disease therapy.
    Torres VE; Harris PC
    Nat Rev Nephrol; 2011 Dec; 8(2):66-8. PubMed ID: 22158473
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Recent advances in molecular pathogenesis and treatment of polycystic kidney disease].
    Covic M; Covic M
    Rev Med Chir Soc Med Nat Iasi; 2008; 112(1):11-20. PubMed ID: 18677899
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated TGFbeta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease.
    Hassane S; Leonhard WN; van der Wal A; Hawinkels LJ; Lantinga-van Leeuwen IS; ten Dijke P; Breuning MH; de Heer E; Peters DJ
    J Pathol; 2010 Sep; 222(1):21-31. PubMed ID: 20549648
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PKD: a progress report, new directions in research.
    Cowley B
    Nephrol News Issues; 2005 Nov; 19(12):39-40. PubMed ID: 16315542
    [No Abstract]   [Full Text] [Related]  

  • 39. What drives cyst formation in PKD?
    Bagherie-Lachidan M; McNeill H
    J Am Soc Nephrol; 2010 Feb; 21(2):200-2. PubMed ID: 20075067
    [No Abstract]   [Full Text] [Related]  

  • 40. Manipulation of renal gene expression using oligonucleotides.
    Lakhia R; Mishra A; Patel V
    Methods Cell Biol; 2019; 154():109-120. PubMed ID: 31493813
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.